Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1682
    +0.0026 (+0.22%)
     

  • GBP/USD

    1.2493
    -0.0018 (-0.14%)
     

  • Bitcoin GBP

    51,150.73
    -648.37 (-1.25%)
     

  • CMC Crypto 200

    1,332.20
    -64.33 (-4.61%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,350.50
    +8.00 (+0.34%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Investigation Report on China's CNY1.112 Billion Docetaxel Market 2021-2025

Research and Markets
·4-min read

Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Docetaxel Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

According to the market research, the sales value of Docetaxel in the Chinese market remained constant from 2016 to 2019. Due to the impact of the COVID-19 epidemic on China's hospital's overall diagnosis and treatment services, the sales value of Docetaxel in the Chinese market decreased to CNY1.112 billion in 2020, a year-on-year decrease of 16.79%. The CAGR of the sales value of Docetaxel in the Chinese market from 2016 to 2020 was -3.86%.

Docetaxel, sold under the brand name Taxotere, is a paclitaxel anti-tumor drug used for the treatment of locally advanced or metastatic non-small cell lung cancer. Docetaxel injection was first developed and produced by the French company Rhone Planck Lean (later renamed Aventis, also known as Sanofi-Aventis). It was first approved for marketing by the European Union in 1995 and approved in China in 1996. By 2020, there were several manufacturers in the Chinese Docetaxel market.

The analyst expects that with the alleviation of the COVID-19 epidemic, sales of Docetaxel will have a restorative growth from 2021 to 2025. In addition, 4.57 million new cancer cases were diagnosed in China in 2020, and the overall cancer incidence increased by about 3.9% annually.

Therefore, the sales volume of Docetaxel for the treatment of locally advanced or metastatic non-small cell lung cancer will increase with the increase of colon cancer patients and there is room for sales to rise. At the same time, compared with similar drugs, Docetaxel is safer and more effective, the sales volume will grow in the future.

Topics Covered:

  • The impact of COVID-19 on China's Docetaxel market

  • Sales value of China's Docetaxel 2016-2020

  • Competitive landscape of China's Docetaxel market

  • Prices of Docetaxel in China

  • Prices of Docetaxel in China by regions and manufacturers

  • Analysis of factors affecting the development of China's Docetaxel market

  • Prospect of China's Docetaxel market from 2021 to 2025

ADVERTISEMENT

Key Topics Covered:

1 Relevant Concepts of Docetaxel
1.1 Indications for Docetaxel
1.2 Development of Docetaxel in China
1.3 Governmental Approval of Docetaxel in China
1.4 The Impact of COVID-19 on Docetaxel Sales in China

2 Sales of Docetaxel in China, 2016-2020
2.1 Sales Value of Docetaxel
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Docetaxel
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Docetaxel by Dosage Form in China, 2016-2020
2.3.1 Injection
2.3.2 Analysis of Other Dosage Form

3 Analysis of Major Docetaxel Manufacturers in China in 2020
3.1 Analysis of Market Share of Major Docetaxel Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Aventis Pharma SA
3.2.1 Enterprise Profile
3.2.2 Sales of TAXOTERE (Aventis Pharma SA's Docetaxel) in China
3.3 Jiangsu Hengrui Medicine Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Aisu (Jiangsu Hengrui Medicine Co., Ltd.'s Docetaxel) in China
3.4 Shenzhen Wanle Pharmaceutical Co.,Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Xichun (Shenzhen Wanle Pharmaceutical Co.,Ltd.'s Docetaxel) in China
3.5 Sichuan Huiyu Pharmaceutical Co., Ltd.
3.5.1 Enterprise Profile
3.5.2 Sales of Huiyu (Sichuan Huiyu Pharmaceutical Co., Ltd.'s Docetaxel) in China
3.6 Yangtze River Pharmaceutical Group Co.,Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Tianlun (Yangtze River Pharmaceutical Group Co.,Ltd.'s Docetaxel) in China

4 Prices of Docetaxel for Different Manufacturers in China, 2020-2021
4.1 Aventis Pharma SA (TAXOTERE)
4.2 Jiangsu Hengrui Medicine Co., Ltd. (Aisu)
4.3 Shenzhen Wanle Pharmaceutical Co., Ltd. (Xichun)
4.4 Sichuan Huiyu Pharmaceutical Co., Ltd. (Huiyu)
4.5 Yangtze River Pharmaceutical Group Co.,Ltd. (Tianlun)

5 Prospect of Chinese Docetaxel Market, 2021-2025
5.1 Influential Factors of Chinese Docetaxel Market Development
5.1.1 The Impact of COVID-19 on Chinese Docetaxel Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

Companies Mentioned

  • Aventis Pharma SA

  • Jiangsu Hengrui Medicine Co. Ltd.

  • Shenzhen Wanle Pharmaceutical Co. Ltd.

  • Sichuan Huiyu Pharmaceutical Co. Ltd.

  • Yangtze River Pharmaceutical Group Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/55fhaa

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900